Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

Johnson & Johnson (JNJ) is highlighted as a compelling momentum stock, currently holding a Zacks Rank of #3 (Hold) and a VGM Score of B. The company's shares have risen 5.4% in the past four weeks, supported by a Momentum Style Score of B and upward revisions from eight analysts for fiscal year 2025, increasing the consensus estimate to $10.60 per share; JNJ's diversified business model and substantial R&D budget further contribute to its appeal.

Analysis

Johnson & Johnson (JNJ) is presented as a stock with notable momentum characteristics, despite its current Zacks Rank of #3 (Hold). The company's shares have appreciated by 5.4% over the past four weeks, a performance underscored by a Momentum Style Score of B. This positive trajectory is further supported by upward revisions in earnings estimates for fiscal 2025 from eight analysts within the last 60 days, which has elevated the Zacks Consensus Estimate by $0.06 to $10.60 per share. JNJ also demonstrates a consistent ability to outperform expectations, evidenced by an average earnings surprise of 5.7%. The company's fundamental appeal is rooted in its highly diversified business model, encompassing pharmaceuticals and medical devices through over 275 subsidiaries, and featuring 26 distinct platforms each generating over $1 billion in annual sales. This extensive diversification, combined with one of the largest R&D budgets in the pharmaceutical industry, contributes to its resilience against economic fluctuations. A VGM Score of B, according to Zacks, also indicates a balanced profile, suggesting that JNJ merits attention from investors, especially for a stock with a Hold rating.

Key Decisions for Investors

• Investors should note JNJ's recent 5.4% share price increase and the upward revision of its fiscal 2025 earnings consensus to $10.60 as positive near-term signals.
• Given the Zacks Rank #3 (Hold) is accompanied by favorable Momentum (B) and VGM (B) Style Scores, JNJ warrants consideration for a watchlist, particularly for those valuing its diversified business model and substantial R&D investment.
• Continued positive earnings estimate revisions and sustained price momentum should be closely monitored as potential catalysts for reassessing positions or identifying entry points, especially if supportive of long-term momentum characteristics.